ClinicalTrials.gg
Active, not recruitingNCT06581198Updated Sep 2, 2026

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

A Phase 2 interventional study of rapcabtagene autoleucel in Lupus Erythematosus, Systemic and Lupus Nephritis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 107 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Primary conditionLupus NephritisRegistry: Lupus Erythematosus, SystemicReclassifiedWhy we changed it
Registry
Lupus Erythematosus, Systemic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lupus Nephritis
Why
  1. The study's listed conditions name Lupus Nephritis, a narrower term within Lupus Erythematosus, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
179
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Lupus Nephritis by Novartis — 1 open to participants now, 3 under way, 2 of them phase 3. Lupus Nephritis · Novartis.

Started
2024
the only one that year
Phase 2
4 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Lupus Nephritis by Novartis, this one is the only one that started in 2024, is one of 4 in phase 2, and was the 9th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

1 of the 10 studies in Lupus Nephritis by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lupus Nephritis by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

03

Conditions studied

  • Lupus Erythematosus, Systemic
  • Lupus Nephritis

Browse trials for

Keywords

  • Chimeric Antigen Receptor-T (CAR-T)
  • rapcabtagene autoleucel
  • Lupus Nephritis (LN)
  • Systemic Lupus Erythematosus (SLE)
04

In context

Lupus Nephritis Reclassified

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

This study's planned enrollment of 179 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.

Browse Lupus Nephritis studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Lupus Nephritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lupus Erythematosus, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Men and women with SLE, aged >= 18 years and =\< 75 years at screening, fulfilling the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE at screening.
  • Participant must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of >= 1:80 (on HEp-2 cells or an equivalent positive test), or anti-dsDNA (above the ); or anti-Sm (above the ULN) as determined by a central laboratory.
  • Active lupus nephritis without signs of significant chronicity or active systemic lupus erythematosus
  • SLEDAI-2K Criteria at screening: SLEDAI-2K score >= 6 points (Gladman et al 2002, Touma et al 2011), excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome".
  • Inadequate response at screening to at least two therapies

Key Exclusion Criteria:

  • Any acute, severe lupus related-flare at screening that needs immediate treatment other than pulse GCs and/or makes the washout impossible and, thus, makes the participant ineligible for CD19 CAR-T therapy
  • Inadequate organ function during screening and prior to randomization
  • History or current diagnosis of or cardiac abnormalities indicating significant risk of safety for participants prior to randomization
  • (HIV) positivity at screening.
  • Acute or chronic infection with (HBV) or (HCV) at screening.
  • Grade 2 or higher thromboembolic event in the past 4 weeks prior to screening.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
179 participants (estimated)

Study arms

  • Experimental
    rapcabtagene autoleucel

    rapcabtagene autoleucel

    Biological: rapcabtagene autoleucel

Interventions

07

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of rapcabtagene autoleucel

    Defined as: Meeting the criteria of the Definition Of Remission In Systemic Lupus Erythematosus (DORIS) or Achieving complete renal response (CRR)

    Time frame: Week 24, Week 52

Secondary outcomes

  1. Percentage of participants achieving complete renal response (CRR)

    CRR is a composite endpoint

    Time frame: Week 52

  2. Number of weeks where Lupus Low Disease Activity Score (LLDAS) was achieved

    Lupus Low Disease Activity State (LLDAS)

    Time frame: Week 12 to Week 52

  3. PPercentage of participants without flaring (i.e., 1 new BILAG2004 A or 2 new BILAG2004 B flares)

    British Isles Lupus Activity Group (BILAG2004) records disease activity occurring over the past 4 weeks.

    Time frame: Week 12 to Week 52

  4. Annualized cumulative corticosteroids dose

    The total dose of corticosteroids used up to Week 52 per patient.

    Time frame: Week 52

  5. Percentage of participants who are negative for serological status

    The percentage of participants with negative serological status

    Time frame: Week 52

  6. FACIT-Fatigue score change from baseline

    Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue is a 13-item patient- reported outcomes measure

    Time frame: Baseline to Week 52

  7. Maintained DORIS

    Definition Of Remission In Systemic Lupus Erythematosus (DORIS)

    Time frame: Week 52 to Week 76

08

Study locations

107 sites
  • University Of Alabama
    Birmingham, Alabama 35294, United States
  • Loma Linda University
    San Bernardino, California 92408, United States
  • UCSF
    San Francisco, California 94115, United States
  • Sutter Health Network
    San Pablo, California 94806, United States
  • Ann and Robert H Lurie Childs Hosp
    Chicago, Illinois 60611, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University Of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kentucky
    Lexington, Kentucky 40536-0284, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • WA Uni School Of Med
    St Louis, Missouri 63110, United States
  • Duke Clinical Research Institute
    Durham, North Carolina 27710, United States
  • James Cancer Hospital
    Columbus, Ohio 43210, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Univ Of TX MD Anderson CC
    Houston, Texas 77030, United States
  • LDS Hospital
    Salt Lake City, Utah 84143, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1118AAT, Argentina
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016KEH, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Salvador, Estado de Bahia 41253-190, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 80030-110, Brazil
  • Novartis Investigative Site
    Barretos, São Paulo 14784-400, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01232-010, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01308-050, Brazil
  • Novartis Investigative Site
    São Paulo, 01509-010, Brazil
  • Novartis Investigative Site
    Olomouc, 779 00, Czechia
  • Novartis Investigative Site
    Prague, 128 00, Czechia
  • Novartis Investigative Site
    Prague, 128 08, Czechia
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Clermont-Ferrand, 63003, France
  • Novartis Investigative Site
    Marseille, 13005, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Paris, 75014, France
  • Novartis Investigative Site
    Strasbourg, 67091, France
  • Novartis Investigative Site
    Toulouse, 31054, France
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
  • Novartis Investigative Site
    Stuttgart, Baden-Wurttemberg 70376, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60528, Germany
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Nuremberg, 90419, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Alessandria, AL 15121, Italy
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Milan, MI 20132, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Pescara, PE 65124, Italy
  • Novartis Investigative Site
    Pisa, PI 56126, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Chiba, Chiba 2608677, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608648, Japan
  • Novartis Investigative Site
    Kobe, Hyōgo 6500047, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 2360004, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 9808574, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Izumo, Shimane 6938501, Japan
  • Novartis Investigative Site
    Bunkyo Ku, Tokyo 1138431, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 1138519, Japan
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
  • Novartis Investigative Site
    Ishikawa, 9208641, Japan
  • Novartis Investigative Site
    Kyoto, 6068507, Japan
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Groningen, Provincie Groningen 9713 GZ, Netherlands
  • Novartis Investigative Site
    Leiden, South Holland 2333 ZA, Netherlands
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Oslo, 0372, Norway
  • Novartis Investigative Site
    Poznan, Greater Poland Voivodeship 60-355, Poland
  • Novartis Investigative Site
    Lodz, 92-213, Poland
  • Novartis Investigative Site
    Bucharest, 022328, Romania
  • Novartis Investigative Site
    Riyadh, 11211, Saudi Arabia
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
  • Novartis Investigative Site
    Seoul, 04763, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain

Showing the first 100 of 107 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Feb 2028, 41 months after the start.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 41 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Sep 3, 2024
StartActual
Sep 4, 2024
Primary completionEst.
Feb 14, 2028
CompletionEst.
Feb 6, 2032
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06581198
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Sep 4, 2024
Primary completion
Feb 14, 2028 (estimated)
Completion
Feb 6, 2032 (estimated)
Last update
Sep 2, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rapcabtagene autoleucel

Start the discussion